___

• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137: 1142–62, 1973.
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392: 245–52, 1998.
• Ardavin C, Martinez del Hoyo G, Martin P et al. Origin and differentiation of dendritic cells. Trends Immunol 22: 691–700, 2001.
• Wykes M, Pombo A, Jenkins C et al. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 161: 1313–19, 1998.
• Cella M, Scheidegger D, Palmer-Lehmann K et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747–52, 1996.
• Brasel K, De Smedt T, Smith JL et al. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96: 3029–39, 2000.
• Shimizu Y, Guidotti LG, Fowler P et al. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 161: 4520–29, 1998.
• Spranger S, Javorovic M, Burdek M et al. Generation of Th1- polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185: 738–47, 2010.
• FDA. Approval Letter – Provenge, 2010. Food and Drug Administration. Washington DC; 2010. Available at http://www. fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/ucm210215.htm
• WHO. Hepatitis B vaccines WHO position paper, 2006. World Health Organization. Geneva; 2006. Available at http://www. who.int/immunization/topics/WHO_position_paper_HepB. pdf.
• WHO. Hepatitis B, 2000. World Health Organization. Geneva; 2000. Available at http://www.who.int/mediacentre/factsheets/ fs204/en/.
• Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54: 1286–96, 2011.
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 359: 1486–1500, 2008.
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology 137: 1593–1608, 2009.
• Furukawa S, Akbar SMF, Hasabe A et al. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 209: 551–57, 2004.
• Jiang WZ, Fan Y, Liu Y et al. Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice. Antivir Res 77: 50–5, 2008.
• Luo J, Li J, Chen RL et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 28: 2497–504, 2010.
• Lou Y, Liu C, Kim GJ et al. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178: 1534–41, 2007.
• Chen W, Zhang Z, Shi M et al. Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 cell response. Clin Immunol 129: 295–303, 2008.
• Akbar SMF, Furukawa S, Yoshida O et al. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 47: 60–6, 2007.
• Randall RE, Young DF, Southern JA. Immunization with solid matrix-antibody-antigen complexes containing surface or internal virus structural proteins protects mice from infection with the paramyxovirus, simian virus 5. J Gen Virol 69: 2517– 26, 1988.
• Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25: 1771–79, 2007.
• Wen YM, Wu XH, Hu DC et al. Hepatitis B vaccine and anti- HBs complex as approach for vaccine therapy. Lancet 345: 1575–76, 1995.
• Wen Y. Antigen–antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Th 9: 285–91, 2009.
• Bagis H, Arat S, Mercan HO et al. Stable transmission and expression of the hepatitis B virus total genome in hybrid transgenic mice until F10 generation. J Exp Zool Part A 305: 420–27, 2006.
• Başalp A, Yücel F. Development of mouse hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node and bone marrow. Hybridoma Hybridom 22: 329– 31, 2003.
• Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol-Mech 1: 23–61, 2006.
• Asavaroengchai W, Kotera Y, Mulé JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. P Natl Acad Sci USA 99: 931–36, 2002.
• You H, Liu Y, Cong M et al. HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J Viral Hepatitis 13: 605–12, 2006.
• Lesterhuis WJ, De Vries IJ, Schreibelt G et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30: 5091–97, 2010.
• Steele JC, Rao A, Marsden JR et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 18: 584–93, 2011.
• Bishop NJ, Morley R, Day JP et al. Aluminum neuro toxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med 336: 1557–1561, 1997.
• Wang M, Chen JT, Ruan DY et al. The influence of developmental period of aluminum exposure on synaptic plasticity in the adult rat dentate gyrus in vivo. Neuroscience 113: 411–419, 2002.
• Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem 18: 2630–37, 2011.
• Flach TL, Ng G, Hari A et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 17: 479–87, 2002.
• Glenny AT, Pope CG, Waddington H et al. Immunological notes: XVII–XXIV. J Pathol Bacteriol 29: 31–40, 1926.
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287– 93, 2009.
• Sun H, Pollock KG, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21: 849–55, 2003.
• Morefield GL, Sokolovska A, Jiang D et al. Role of aluminumcontaining adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23: 1588–95, 2005.